Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;11(10):599-609.
doi: 10.1038/nrneph.2015.95. Epub 2015 Jun 30.

IgG4-related disease and the kidney

Affiliations
Review

IgG4-related disease and the kidney

Frank B Cortazar et al. Nat Rev Nephrol. 2015 Oct.

Abstract

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition that involves almost every organ system. In this Review, we summarize current knowledge of IgG4-RD and its most frequent manifestations in the kidney—IgG4-related tubulointerstitial nephritis (TIN) and membranous glomerulonephropathy (MGN). Diagnosis of IgG4-RD relies on histopathology: the typical features are a dense lymphoplasmacytic infiltrate and storiform fibrosis. A high percentage of plasma cells observed within lesions stain positively for IgG4. IgG4-related TIN bears the hallmark pathological findings of IgG4-RD; distinctive radiographic characteristics are also frequently observed with use of contrast-enhanced CT. MGN secondary to IgG4-RD seems to be distinct from idiopathic MGN. Humoral and cell-mediated immunity seem to have roles in the pathophysiology of IgG4-RD, but the details of these roles remain unclear. The IgG4 molecule itself is unlikely to be the primary driver of inflammation; rather, it probably downregulates the immune response. Fibrosis might be caused by activation of innate immune cells by polarized CD4(+) T cells. Glucocorticoids are the standard initial treatment for IgG4-RD, but their long-term adverse effects and the high frequency of relapse and renal damage associated with use of this treatment has prompted a search for more effective options. B-cell depletion and the targeting of plasmablasts are both promising approaches.

PubMed Disclaimer

Similar articles

  • IgG4-related kidney disease--an update.
    Kawano M, Saeki T. Kawano M, et al. Curr Opin Nephrol Hypertens. 2015 Mar;24(2):193-201. doi: 10.1097/MNH.0000000000000102. Curr Opin Nephrol Hypertens. 2015. PMID: 25594543 Free PMC article. Review.
  • IgG4-Related Tubulointerstitial Nephritis.
    Zhang P, Cornell LD. Zhang P, et al. Adv Chronic Kidney Dis. 2017 Mar;24(2):94-100. doi: 10.1053/j.ackd.2016.12.001. Adv Chronic Kidney Dis. 2017. PMID: 28284385 Review.
  • [IgG4-related kidney disease. Diagnosis and treatment].
    Kawano M, Mizushima I, Yamada K, Taniguchi Y, Saeki T. Kawano M, et al. Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(1):8-16. doi: 10.2177/jsci.38.8. Nihon Rinsho Meneki Gakkai Kaishi. 2015. PMID: 25765684 Review. Japanese.
  • IgG4-related nephropathy.
    Quattrocchio G, Roccatello D. Quattrocchio G, et al. J Nephrol. 2016 Aug;29(4):487-93. doi: 10.1007/s40620-016-0279-4. Epub 2016 Mar 14. J Nephrol. 2016. PMID: 26972314 Review.
  • IgG4-related kidney disease--A review.
    Pradhan D, Pattnaik N, Silowash R, Mohanty SK. Pradhan D, et al. Pathol Res Pract. 2015 Oct;211(10):707-11. doi: 10.1016/j.prp.2015.03.004. Epub 2015 May 14. Pathol Res Pract. 2015. PMID: 26341570 Review.

Cited by

References

    1. Ann Rheum Dis. 2015 Jan;74(1):14-8 - PubMed
    1. Annu Rev Pathol. 2014;9:315-47 - PubMed
    1. Int J Rheumatol. 2012;2012:609795 - PubMed
    1. Clin Exp Allergy. 2009 Apr;39(4):469-77 - PubMed
    1. Gut. 2009 Nov;58(11):1504-7 - PubMed

MeSH terms

Substances